Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355962 | 1.00 | KMT2A (0.50) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL7701655 | 0.87 | KMT2A (0.60) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL7704690 | 0.83 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL22355972 | 0.80 | KMT2A (0.56) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL22356140 | 0.80 | KMT2A (0.56) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL7701652 | 0.80 | KMT2A (0.60) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL7512529 | 0.78 | ALDH1A1 (0.64) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL7512534 | 0.78 | ALDH1A1 (0.64) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL8997426 | 0.78 | ALDH1A1 (0.64) | KMT2AMEN1KLK7ALDH1A1CYP3A4 | |
| SCHEMBL18206262 | 0.78 | KMT2A (0.50) | KMT2AMEN1KLK7ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | KMT2A 1328/4885MEN1 4433/4885KLK7 4294/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | KMT2A 1389/4885MEN1 4474/4885KLK7 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.